Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 23, 2002

View Archived Issues

Treatment with statins reported not to be related to a higher risk for breast cancer

DT388-GM-CSF is effective against refractory acute myeloid leukemia but causes liver injury

Thalidomide reported to be effective in the short-term treatment of symptomatic IBD

Soybean phytosterols induce hypocholesterolemic effects in young adult men

STO-609, a potent and selective CaM-KK inhibitor synthesized at Sumitomo

HGF, a rapid diagnostic marker and preventative treatment for acute renal rejection

Buprenorphine transdermal therapeutic system is effective in relieving chronic pain

Chromium picolinate improves carbohydrate and lipid metabolism in obese hyperinsulinemic rats

Novel HDAC inhibitors in early development at Roche

Novel 5-HT2C modulators prepared and tested at Roche and Vernalis

New tachykinin NK1 antagonists identified by AstraZeneca researchers

New muscarinic antagonists and their use in cognitive and neurodegenerative disorders

Bayer claims new thyroid-like compounds for lipoprotein disorders

Latest FDA approval for Kytril is for prevention and treatment of postoperative nausea and vomiting

Myriad Genetics files IND with FDA for new Alzheimer's treatment

Clinical trial commences for squalamine in treatment of AMD

Novel nonprostanoid EP4 antagonist prepared and tested at GSK

In vitro and in vivo studies on bone-healing agent CP-533536 reported at ACS

FDA issues non approval letter for Helicide

New 5-HT2C agonist and its use in erectile dysfunction discussed at ACS meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...